These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 9893005)

  • 1. Drug update: trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer.
    Wong WM
    Cancer Pract; 1999; 7(1):48-50. PubMed ID: 9893005
    [No Abstract]   [Full Text] [Related]  

  • 2. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
    Shak S
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
    Tokuda Y; Suzuki Y; Saito Y; Umemura S
    Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on Trastuzumab in the management of HER2-positive metastatic and early-stage breast cancer.
    Plosker GL; Keam SJ
    BioDrugs; 2006; 20(4):259-62. PubMed ID: 16831025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
    Hortobagyi GN
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More than one way to look for HER2.
    Check W
    CAP Today; 1999 Mar; 13(3):1, 40-2, 46, passim. PubMed ID: 10350906
    [No Abstract]   [Full Text] [Related]  

  • 8. [Trastuzumab in metastatic breast carcinoma].
    Susnjar S; Bosnjak S; Radulovic S
    Srp Arh Celok Lek; 2001; 129(5-6):147-52. PubMed ID: 11797464
    [No Abstract]   [Full Text] [Related]  

  • 9. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased HER2 with U.S. Food and Drug Administration-approved antibody.
    Roche PC; Ingle JN
    J Clin Oncol; 1999 Jan; 17(1):434. PubMed ID: 10458264
    [No Abstract]   [Full Text] [Related]  

  • 12. Controversies in the use of adjuvant trastuzumab (Herceptin).
    Chowdhury S; Pickering L; Ellis P
    J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab treatment beyond brain progression in HER2- positive metastatic breast cancer.
    Kilickap S; Arslan C
    Ann Oncol; 2009 Jan; 20(1):192. PubMed ID: 19172706
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibodies as molecular target-based therapy: trastuzumab.
    Tokuda Y
    Int J Clin Oncol; 2003 Aug; 8(4):224-9. PubMed ID: 12955577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of antibody therapy for breast cancer.
    Toi M; Takada M; Bando H; Toyama K; Yamashiro H; Horiguchi S; Saji S
    Breast Cancer; 2004; 11(1):10-4. PubMed ID: 14718785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 therapy: molecular mechanisms of trastuzumab resistance.
    Nahta R; Esteva FJ
    Breast Cancer Res; 2006; 8(6):215. PubMed ID: 17096862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical implications of trastuzumab].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909-914).
    Bonneterre ME; Bonneterre J
    Ann Oncol; 2006 May; 17(5):875; reply 875-6. PubMed ID: 16303862
    [No Abstract]   [Full Text] [Related]  

  • 19. A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody.
    Ohta M; Tokuda Y; Suzuki Y; Kubota M; Watanabe T; Fujii H; Sasaki Y; Niwa T; Makuuchi H; Tajima T
    Jpn J Clin Oncol; 2001 Nov; 31(11):553-6. PubMed ID: 11773264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herceptin: from the bench to the clinic.
    Colomer R; Shamon LA; Tsai MS; Lupu R
    Cancer Invest; 2001; 19(1):49-56. PubMed ID: 11291556
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.